BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26057149)

  • 21. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells.
    Port RJ; Pinheiro-Maia S; Hu C; Arrand JR; Wei W; Young LS; Dawson CW
    J Pathol; 2013 Nov; 231(3):367-77. PubMed ID: 23934731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells.
    Pai S; O'Sullivan BJ; Cooper L; Thomas R; Khanna R
    J Virol; 2002 Feb; 76(4):1914-21. PubMed ID: 11799186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway.
    Stewart S; Dawson CW; Takada K; Curnow J; Moody CA; Sixbey JW; Young LS
    Proc Natl Acad Sci U S A; 2004 Nov; 101(44):15730-5. PubMed ID: 15498875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase.
    Chen SY; Lu J; Shih YC; Tsai CH
    J Virol; 2002 Sep; 76(18):9556-61. PubMed ID: 12186939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas.
    Zhang YW; Zhao XX; Tan C; Zhang ZG; Jiang Y; Chen JN; Wei HB; Xue L; Li HG; Du H; Shao CK
    Oncotarget; 2015 Jan; 6(1):207-20. PubMed ID: 25402957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling.
    Morrison JA; Raab-Traub N
    J Virol; 2005 Feb; 79(4):2375-82. PubMed ID: 15681438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus and gastric carcinoma.
    Fukayama M
    Pathol Int; 2010 May; 60(5):337-50. PubMed ID: 20518883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
    Portis T; Cooper L; Dennis P; Longnecker R
    Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer.
    Qi YF; Liu M; Zhang Y; Liu W; Xiao H; Luo B
    Virus Res; 2019 Oct; 272():197735. PubMed ID: 31473273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
    Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
    J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
    Rancan C; Schirrmann L; Hüls C; Zeidler R; Moosmann A
    PLoS Pathog; 2015 Jun; 11(6):e1004906. PubMed ID: 26067064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
    Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
    Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus latent membrane protein 2A and autoimmunity.
    Swanson-Mungerson M; Longnecker R
    Trends Immunol; 2007 May; 28(5):213-8. PubMed ID: 17398159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A.
    Minamitani T; Yasui T; Ma Y; Zhou H; Okuzaki D; Tsai CY; Sakakibara S; Gewurz BE; Kieff E; Kikutani H
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11612-7. PubMed ID: 26305967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
    Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
    Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.